Industry News

      Exscientia Announces Expansion of its Precision Oncology Pipeline

      OXFORD, England--(BUSINESS WIRE)--Exscientia plc (Nasdaq: EXAI) today announced two new wholly-owned precision oncology development candidates, EXS74539 (‘539), an LSD1 inhibitor, and EXS73565 ('565), a...

      Switch Therapeutics Launches with $52 Million to Advance First-of-its-Kind RNAi Technology

      SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Switch Therapeutics, a preclinical stage biotechnology company pioneering a new way to use RNA science to treat diseases, today announced...

      Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th...

      WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced new data...

      MAIA Biotechnology Announces No Exposure to Silicon Valley Bank

      CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) announced today the Company has no exposure to Silicon Valley Bank (“SVB”). The Company is aware that...

      Recent Articles

      Get a free copy of "Cracking the Generics Code"

      Looks like you are using an ad-blocking browser extension. We request you to whitelist our website on the ad-blocking extension and refresh your browser to view the content.